Cargando…

High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real‐World Administrative Claims Analysis of Statin‐Treated Patients With High Residual Cardiovascular Risk

BACKGROUND: The American Heart Association recognizes high triglycerides as a cardiovascular risk factor. METHODS AND RESULTS: This retrospective observational administrative claims analysis (Optum Research Database) included statin‐treated patients ≥45 years old with diabetes mellitus and/or athero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toth, Peter P., Granowitz, Craig, Hull, Michael, Liassou, Djibril, Anderson, Amy, Philip, Sephy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201477/ https://www.ncbi.nlm.nih.gov/pubmed/30371242 http://dx.doi.org/10.1161/JAHA.118.008740

Ejemplares similares

Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin‐controlled LDL cholesterol
por: Nichols, Gregory A., et al.
Publicado: (2018)

Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200–499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients
por: Toth, Peter P, et al.
Publicado: (2019)

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
por: Leatherman, Sarah, et al.
Publicado: (2022)

Hypertriglyceridemia is associated with an increased risk of peripheral arterial revascularization in high‐risk statin‐treated patients: A large administrative retrospective analysis
por: Toth, Peter P., et al.
Publicado: (2019)

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study
por: Ballantyne, Christie M., et al.
Publicado: (2019)

Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2020)

Prevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014
por: Fan, Wenjun, et al.
Publicado: (2019)

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis
por: Brinton, Eliot A., et al.
Publicado: (2018)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Triglycerides and Cardiovascular Risk
por: Harchaoui, K.E.L, et al.
Publicado: (2009)

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
por: Toth, Peter P
Publicado: (2016)

Global assessment improves risk stratification for major adverse cardiac events across a wide range of triglyceride levels: Insights from the KP REACH study
por: Wagner, Jeffrey R., et al.
Publicado: (2022)

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease
por: Gabani, Mohanad, et al.
Publicado: (2023)

Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk
por: Lin, Iris, et al.
Publicado: (2016)

Benefits of statin therapy and compliance in high risk cardiovascular patients
por: Lardizabal, Joel A, et al.
Publicado: (2010)

Re: ‘Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: a meta-analysis’
por: Philip, Sephy
Publicado: (2023)

Cardiovascular Risk and Statin Therapy Considerations in Women
por: Gheorghe, Gina, et al.
Publicado: (2020)

Prognostic value of triglyceride glucose index in population at high cardiovascular disease risk
por: Cai, Xiao-ling, et al.
Publicado: (2023)

Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
por: Rossini, Enrica, et al.
Publicado: (2022)

Predictive Value of the Triglyceride to High-Density Lipoprotein Cholesterol Ratio for All-Cause Mortality and Cardiovascular Death in Diabetic Patients With Coronary Artery Disease Treated With Statins
por: Wang, Le, et al.
Publicado: (2021)

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease
por: Sonmez, Alper, et al.
Publicado: (2015)

Statins; the panacea of cardiovascular disease
por: de Waard, G. A., et al.
Publicado: (2017)

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy
por: Menon, Venu, et al.
Publicado: (2019)

Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
por: Mougalian, Sarah S., et al.
Publicado: (2021)

The Achievement of Non-high-density Lipoprotein Cholesterol Target in Patients with Very High Atherosclerotic Cardiovascular Disease Risk Stratified by Triglyceride Levels Despite Statin-controlled Low-density Lipoprotein Cholesterol
por: Al-Sabti, Hilal, et al.
Publicado: (2022)

Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database
por: Ono, Yasuhisa, et al.
Publicado: (2020)

Correction to: Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States
por: Mougalian, Sarah S., et al.
Publicado: (2021)

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
por: McTaggart, Fergus, et al.
Publicado: (2008)

The Triglyceride-Glucose Index Can Predict Long-Term Major Adverse Cardiovascular Events in Turkish Patients With High Cardiovascular Risk
por: Hayıroğlu, Mert İlker, et al.
Publicado: (2022)

Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study
por: Kristensen, Frederik Pagh Bredahl, et al.
Publicado: (2023)

The Impact of CDH13 Polymorphism and Statin Administration on TG/HDL Ratio in Cardiovascular Patients
por: Choi, Jung Ran, et al.
Publicado: (2015)

Triglyceride and cardiovascular risk: A critical appraisal
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin
por: Mitchell, Dominic, et al.
Publicado: (2016)

Triglyceride to High-Density Lipoprotein Cholesterol Ratio Predicts Cardiovascular Outcomes in Prevalent Dialysis Patients
por: Chen, Hung-Yuan, et al.
Publicado: (2015)

Cardiovascular Disease Risk Assessment: Triglyceride/High-Density Lipoprotein versus Metabolic Syndrome Criteria
por: Gharipour, Mojgan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_og0bhrek8cb9h0hkfm52aq6d39